Purpose COVID-19 as a pandemic calls for rapid development of vaccines. Methods Here a proposal of a seamless, adaptive, phase 1–3 trial for accelerated vaccine development is described. Results Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an interval of 2 weeks; close surveillance of antibody responses, safety and efficacy is necessary. After only 16 weeks, general vaccination would be feasible if supply meets the demand. Conclusion A COVID-19 vaccine would be rapidly available at a slightly increased risk for undetected late side effects or insufficient efficacy if compared with standard vaccine development schemes.
All Keywords
【저자키워드】 COVID-19, vaccination, adaptive design, exponential growth, Seamless trial design, 【초록키워드】 Efficacy, Vaccine development, COVID-19 vaccine, pandemic, Trial, adaptive, Vaccines, antibody, Surveillance, Side effect, increased risk, starting, Volunteer, responses, Result, described, feasible, accelerated, meet, seamless, 【제목키워드】 Vaccine development, Escalation,
【저자키워드】 COVID-19, vaccination, adaptive design, exponential growth, Seamless trial design, 【초록키워드】 Efficacy, Vaccine development, COVID-19 vaccine, pandemic, Trial, adaptive, Vaccines, antibody, Surveillance, Side effect, increased risk, starting, Volunteer, responses, Result, described, feasible, accelerated, meet, seamless, 【제목키워드】 Vaccine development, Escalation,